Patient reported outcomes exploring quality of life in PROC and novel therapeutics: mirvetuximab in recurrent ovarian cancer

Description

Discover how patient-reported outcomes highlight mirvetuximab’s ability to preserve quality of life while delivering meaningful clinical benefits for women with platinum-resistant ovarian cancer.

Presented by:

Larissa Meyer, MD, MPH
University of Texas
MD Anderson Cancer Center
USA

Moderated by:

Floor Backes, MD
The Ohio State University Wexner Medical Center
James Comprehensive Cancer Center
USA

Supported in part by

Summary

Availability:

On-Demand

Cost:

FREE

Create Account